Importantly, in HCV+ HCC patients, positive CNPY2 expression was associated with poorer cumulative (log-rank test; p = 0.041) survival, higher clinico-pathological stage (p = 0.016), pT factor (p = 0.016), poor histological tumor differentiation (p = 0.035) and venous invasion (p = 0.038), as compared with its negative expression (Figure 4D and Table 3). This evidence concerns the gene CNPY2 and hepatocellular carcinoma.